Document is current
Any future updates will be listed below
-
Authors
Kim, Seok-Jun
Kang, Hyeok-Gu
Kim, Kyungeun
Kim, Hoyoung
Zetterberg, Fredrik
Park, Young Soo
Cho, Hyun-Soo
Hewitt, Stephen M.
Chung, Joon-Yong
Nilsson, Ulf J.
Leffler, Hakon
Chun, Kyung-Hee
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2014R1A2A1A11050600,NRF-2016R1A5A1010764, NRF-2015M3A9B6073835, NRF-2015M3A9B6073833,, NRF2020R1A2C110007811,NRF-2014R1A1A2055009, NRF-2016K1A3A1A47921595)
Swedish Research Council (No. 2016-07109)
- License Information
-
More Information
Article History
Received: 23 December 2020
Accepted: 21 March 2021
First Online: 8 April 2021
Declarations
:
: F.R.Z. is an employee of and H.L. and U.J.N. are shareholders in Galecto Biotech AB, a company that is developing galectin inhibitors. The other authors have no conflicts to declare.
: All institutional and national guidelines for the care and use of laboratory animals were followed.
Free to read: This content has been made available to all.
